ChromaCode this week launched its first product, a research-use-only test for nine tick-borne pathogens designed for research use on any thermal cycler.
The firm is wrapping up a pre-order period and recently signed a distribution deal with D-Mark Bioscience for the new instrument, called Liberty16.
Researchers hope that understanding the etiology of inappropriate testing will help them design a better computerized support tool.
In the firm's first-ever earnings call, new CEO Jack Kenny said the firm will invest more in R&D to revamp its aging portfolio.
The Elite InGenius has the sample prep capabilities typical of high-throughput platforms, yet it can run more samples than smaller instruments.
Columbia University researchers have adapted a capture-based targeted sequencing method for viral genomes to detect bacteria in clinical samples.
ARMADA began as a consortium of eight US organizations but has increased to 50 institutions in 20 countries and signed on actor Bill Pullman as a spokesman.
The so-called enVision HPV test performed well in a comparison to Roche's Cobas HPV assay, and the Singapore researchers are considering other test applications.
The Belgian company also provided an update on its flagship PCR analysis software and outlined current and future business endeavors.
The technology works directly from clinical samples and can potentially be multiplexed to detect tens of targets, according to the firm.
A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.
South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.
In Science this week: the synthetic genetic system hachimoji, and more.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.